Pharmacoeconomics: (2) Economic evaluations

Pharmaceutical Journal

Volumn 271, Issue 7276, 2003, Pages 716-718

  Fleurence, Rachael ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SIBUTRAMINE;

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG INDUSTRY; ECONOMIC EVALUATION; HEALTH CARE POLICY; NATIONAL HEALTH SERVICE; NOTE; PHARMACOECONOMICS; QUALITY OF LIFE; RESOURCE ALLOCATION;

EID: 0344014175     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (6)

1. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:275-83.
2. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17:479-500.
3. National Institute for Clinical Excellence. Guidance on sibutramine for obesity. Available at: www.nice.org.uk (accessed 29 May 2003).
4. CancerBACUP. Data on access to Herceptin. Available at: www. cancerbacup.org.uk (accessed 22 October 2003).
5. Health Technology Assessment. HTA Web pages. Available at: www.hta.nhsweb.nhs.uk (accessed 29 May 2003).
6. NHS Centre For Reviews and Dissemination. NHS EED web pages. Available at: www.york.ac.uk/inst/crd/ (accessed 29 May 2003).